Our team offers the only FDA approved minimally invasive treatment alternative for thoracic aortic aneurysms in Alaska.
Catheter delivery through a small incision
Now, for the first time, there is a less-invasive method of treating thoracic aortic aneurysms.
Unlike traditional open surgery that involves a large chest incision and prolonged aortic clamping, the GORE TAG Device is inserted through a small incision in the femoral or iliac arteries, advanced to the appropriate location, and deployed to exclude the aneurysm.
Patients with a thoracic aortic aneurysm (TAA) risk death due to internal bleeding resulting from a rupture of their aneurysm. Unfortunately, this life-threating condition is generally believed to be signifcantly under-diagnosed because most affected individuals are asymptomatic.
Until now, the only treatment available was invasive open surgery requiring an incision large enough to allow a synthetic graft to be sewn into place.
Endovascular Procedure versus Open Surgical Repair
The new GORE TAG Endoprosthesis can have a profound impact on the lives of patients with TAA. The following Pivotal Trial evidence demonstrates the advantages of a minimally invasive TAA procedure vs. open surgery.
The GORE TAG Thoracic Endoprosthesis Pivotal Trial demonstrated the TAG Device group as compared to an open surgical control group had:
- One-fifth the paraplegia rate (3% vs. 14%)
- One-sixth the operative mortality rate (1% vs. 6%)
- 80% less procedural blood loss on average (472 ml vs. 2,402 ml)
- Lower aneurysm-related death through 1 year (3% vs. 10%)
- Shortened average ICU stay (1 day vs. 3 days)
- Shortened average hospital stay (3 days vs. 10 days)
- Two times faster return to normal activity (30 days vs. 78 days)
For more information, please contact us via email, or call (907) 375-2000.